Literature DB >> 20552316

[ICD therapy for the primary prevention of sudden cardiac arrest. The patient after a myocardial infarction].

C W Israel1.   

Abstract

ICD therapy represents a major advance in the treatment of patients with severely impaired left ventricular function after myocardial infarction. While an ICD implantation also remains a valuable option late (>5 years) after myocardial infarction, patients early after this event are at a competitive risk of arrhythmogenic and nonarrhythmogenic cardiac death. Prevention of sudden cardiac death in patients early after myocardial infarction, therefore, just converts the mode of death in a significant number of patients from sudden to nonsudden cardiac death (conversion theory). In patients with a left ventricular ejection fraction (LVEF) of < or =30% after myocardial infarction, implantation of the ICD should, therefore, be postponed to at least 30-40 days after the event. It is, however, not clear how the risk of sudden cardiac death should be approached during this post infarction phase. Similarly, it is not clear if patients with a reduced LVEF post infarction and additional specific risks (nonsustained ventricular tachycardia, atrial fibrillation, bundle branch block, etc.) beyond this single criterion may also benefit from ICD implantation and which risk factors may be relevant. In any case, ICD therapy should avoid right ventricular pacing and shock discharges whenever possible.

Entities:  

Mesh:

Year:  2010        PMID: 20552316     DOI: 10.1007/s00399-010-0084-z

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  34 in total

1.  Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction.

Authors:  Ilan Goldenberg; Anant K Vyas; W Jackson Hall; Arthur J Moss; Hongyue Wang; Hua He; Wojciech Zareba; Scott McNitt; Mark L Andrews
Journal:  J Am Coll Cardiol       Date:  2008-01-22       Impact factor: 24.094

2.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

3.  The clinical implications of cumulative right ventricular pacing in the multicenter automatic defibrillator trial II.

Authors:  Jonathan S Steinberg; Avi Fischer; Paul Wang; Claudio Schuger; James Daubert; Scott McNitt; Mark Andrews; Mary Brown; W Jackson Hall; Wojciech Zareba; Arthur J Moss
Journal:  J Cardiovasc Electrophysiol       Date:  2005-04

4.  Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators.

Authors:  M J Domanski; S Sakseena; A E Epstein; A P Hallstrom; M A Brodsky; S Kim; S Lancaster; E Schron
Journal:  J Am Coll Cardiol       Date:  1999-10       Impact factor: 24.094

5.  Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator.

Authors:  Arthur J Moss; Henry Greenberg; Robert B Case; Wojciech Zareba; W Jackson Hall; Mary W Brown; James P Daubert; Scott McNitt; Mark L Andrews; Adam D Elkin
Journal:  Circulation       Date:  2004-12-06       Impact factor: 29.690

6.  Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study.

Authors:  R Sheldon; S Connolly; A Krahn; R Roberts; M Gent; M Gardner
Journal:  Circulation       Date:  2000-04-11       Impact factor: 29.690

7.  Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.

Authors:  J A Cairns; S J Connolly; R Roberts; M Gent
Journal:  Lancet       Date:  1997-03-08       Impact factor: 79.321

8.  The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction.

Authors:  J T Bigger; J L Fleiss; R Kleiger; J P Miller; L M Rolnitzky
Journal:  Circulation       Date:  1984-02       Impact factor: 29.690

9.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

10.  Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study.

Authors:  Alfred E Buxton; Kerry L Lee; Gail E Hafley; Luis A Pires; John D Fisher; Michael R Gold; Mark E Josephson; Michael H Lehmann; Eric N Prystowsky
Journal:  J Am Coll Cardiol       Date:  2007-09-04       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.